A middle-aged man was recently diagnosed with poor prognosis myelodysplastic syndrome (MDS). He was prescribed a course of subcutaneous azacitidine. One week after the first cycle (7 days) of the drug, he presented with pain over the injection sites (over his anterior abdominal wall), associated with high fever and weight loss. He was admitted to […]